Mesothelin is a Malignant Factor and Therapeutic Vaccine Target for Pancreatic Cancer

Overview

Journal Mol Cancer Ther

Date 2008 Feb 19

PMID 18281514

Citations 99

Authors

Min Li

Uddalak Bharadwaj

Rongxin Zhang

Sheng Zhang

Hong Mu

William E Fisher

F Charles Brunicardi

Changyi Chen

Qizhi Yao

Affiliations

Soon will be listed here.

Abstract

Given the high fatality rate of pancreatic cancer, an effective treatment for this devastating disease is urgently needed. We have shown that mesothelin expression was higher in human pancreatic cancer cells than in human pancreatic duct epithelial cells, and mesothelin mRNA was substantially overexpressed in 18 of 21 (86%) clinical pancreatic adenocarcinoma specimens when compared with the surrounding normal tissues. However, the biological functions of mesothelin in tumor progression are not clearly understood. Here we studied the effects of mesothelin overexpression in pancreatic cancer cell proliferation and migration in vitro and pancreatic cancer progression in vivo. We found that forced expression of mesothelin significantly increased tumor cell proliferation and migration by 90% and 300%, respectively, and increased tumor volume by 4-fold in the nude mice xenograft model when compared with the vector control cell line. Silencing of mesothelin inhibited cell proliferation and migration in pancreatic cancer cells and ablated tumor progression in vivo. Vaccination with chimeric virus-like particles that contain human mesothelin substantially inhibited tumor progression in C57BL/6J mice. The increases in mesothelin-specific antibodies and CTL activity and the decrease in regulatory T cells correlated with reduced tumor progression and prolonged survival. This study revealed novel functions of mesothelin and suggested a new therapeutic vaccine strategy whereby mesothelin is targeted to control pancreatic cancer progression.

Citing Articles

Mesothelin (MSLN) is Highly Expressed in Triple Negative Breast Cancer and is Associated with Enhanced Cell Proliferation and Proinflammatory Tumor Microenvironment.

Hagerty B, Sato T, Wu R, Ishikawa T, Takabe K Ann Surg Oncol. 2025; .

PMID: 40080368 DOI: 10.1245/s10434-025-17117-y.

Transplantable Murine Tumors in the Studies of Peptide Antitumor Vaccines.

Ponomarev A, Shubina I, Sokolova Z, Baryshnikova M, Kosorukov V Oncol Rev. 2024; 17:12189.

PMID: 38260723 PMC: 10800450. DOI: 10.3389/or.2023.12189.

Biology of Mesothelin and Clinical Implications: A Review of Existing Literature.

Hagerty B, Takabe K World J Oncol. 2023; 14(5):340-349.

PMID: 37869242 PMC: 10588497. DOI: 10.14740/wjon1655.

Toroidal-spiral particles as a CAR-T cell delivery device for solid tumor immunotherapy.

Tang H, Zaroudi M, Zhu Y, Cheng A, Qin L, Zhang B J Control Release. 2023; 362:620-630.

PMID: 37673306 PMC: 10947521. DOI: 10.1016/j.jconrel.2023.09.005.

Nanoparticle-Mediated Therapy with miR-198 Sensitizes Pancreatic Cancer to Gemcitabine Treatment through Downregulation of VCP-Mediated Autophagy.

Marin-Muller C, Li D, Lu J, Liang Z, Vega-Martinez O, Crawford S Pharmaceutics. 2023; 15(8).

PMID: 37631252 PMC: 10457905. DOI: 10.3390/pharmaceutics15082038.

References

Day J, DiGiuseppe J, Yeo C, Anderson S, Goodman S, Kern S . Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol. 1996; 27(2):119-24. DOI: 10.1016/s0046-8177(96)90364-0. View

Jaffee E, Hruban R, Biedrzycki B, Laheru D, Schepers K, Sauter P . Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001; 19(1):145-56. DOI: 10.1200/JCO.2001.19.1.145. View

Frierson Jr H, Moskaluk C, Powell S, Zhang H, Cerilli L, Stoler M . Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol. 2003; 34(6):605-9. DOI: 10.1016/s0046-8177(03)00177-1. View

Hassan R, Laszik Z, Lerner M, Raffeld M, Postier R, Brackett D . Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2006; 124(6):838-45. View

Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M . Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2003; 279(10):9190-8. DOI: 10.1074/jbc.M312372200. View

Ruedl C, Schwarz K, Jegerlehner A, Storni T, Manolova V, Bachmann M . Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol. 2004; 79(2):717-24. PMC: 538584. DOI: 10.1128/JVI.79.2.717-724.2005. View

Dainty L, Risinger J, Morrison C, Chandramouli G, Bidus M, Zahn C . Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. Gynecol Oncol. 2007; 105(3):563-70. DOI: 10.1016/j.ygyno.2006.10.063. View

Landis S, Murray T, Bolden S, Wingo P . Cancer statistics, 1998. CA Cancer J Clin. 1998; 48(1):6-29. DOI: 10.3322/canjclin.48.1.6. View

Furukawa T, DUGUID W, Rosenberg L, Viallet J, Galloway D, Tsao M . Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol. 1996; 148(6):1763-70. PMC: 1861644. View

10.

Yao Q, Zhang R, Guo L, Li M, Chen C . Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine. J Immunol. 2004; 173(3):1951-8. DOI: 10.4049/jimmunol.173.3.1951. View

11.

Ordonez N . Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol. 2003; 16(3):192-7. DOI: 10.1097/01.MP.0000056981.16578.C3. View

12.

Chang K, Pai L, Batra J, Pastan I, Willingham M . Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res. 1992; 52(1):181-6. View

13.

Zhang R, Li M, Chen C, Yao Q . SHIV virus-like particles bind and activate human dendritic cells. Vaccine. 2004; 23(2):139-47. DOI: 10.1016/j.vaccine.2004.05.036. View

14.

Gubbels J, Belisle J, Onda M, Rancourt C, Migneault M, Ho M . Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006; 5(1):50. PMC: 1635730. DOI: 10.1186/1476-4598-5-50. View

15.

Wei Y, Wang Q, Zhao X, Yang L, Tian L, Lu Y . Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med. 2000; 6(10):1160-6. DOI: 10.1038/80506. View

16.

Maitra A, Adsay N, Argani P, Iacobuzio-Donahue C, De Marzo A, Cameron J . Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol. 2003; 16(9):902-12. DOI: 10.1097/01.MP.0000086072.56290.FB. View

17.

Chackerian B, Lenz P, Lowy D, Schiller J . Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol. 2002; 169(11):6120-6. DOI: 10.4049/jimmunol.169.11.6120. View

18.

DiGiuseppe J, Hruban R, Offerhaus G, Clement M, van den Berg F, Cameron J . Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol. 1994; 144(5):889-95. PMC: 1887369. View

19.

Laheru D, Jaffee E . Immunotherapy for pancreatic cancer - science driving clinical progress. Nat Rev Cancer. 2005; 5(6):459-67. DOI: 10.1038/nrc1630. View

20.

Hassan R, Bera T, Pastan I . Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004; 10(12 Pt 1):3937-42. DOI: 10.1158/1078-0432.CCR-03-0801. View